A new muscle relaxant for the treatment of spasticity, including from spinal cord injuries.
A new muscle relaxant for the treatment of spasticity, including from spinal cord injuries.
Nearly 500 stakeholders share their thoughts on industry challenges and priorities.
Proposed changes are open to public comment until April 11th.
After a drop in activity due to the pandemic, five states are now considering legislation.
Healthe’s VP of Industry and State Affairs, Sandy Shtab, joined an educational webinar from IAIABC.
Buprenorphine is an opioid used to treat pain, as well as opioid-use disorder.
Legislation could potentially reclassify gig workers as employees entitled to workers’ comp.
Drug advancements surrounding the prevention and treatment of COVID-19.
Since the start of 2022, at least 10 states are considering some form of marijuana legislation.
Healthe’s Director of Product Management talks to Risk & Insurance on how to attract and retain talent in the workers’ comp industry.
This autoimmune drug was approved for various arthritic and autoimmune diseases.
The initial results from a collaborative survey between Healthe and Risk & Insurance.®
Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.
New five-day rules are recommended, with variation depending upon vaccination status.
The Bureau of Labor Statistics reports that 4.5 million employees quit their jobs in November 2021.
Healthe’s SVP of Product Strategy and Innovation, Kristine Kennedy, discusses this topic with Risk & Insurance magazine.
Molnupiravir, Paxlovid, and AZD7442 have shown promise in Phase 3 trials.
Those previously infected by the virus may face long-term health complications.
A new study found that VR sessions averaged a 40% reduction in pain and decreased opioid use.
Rulings from U.S. District Courts have impeded vaccine requirements among certain workers.
All adults may now receive a booster shot of any COVID-19 vaccine.
A new naloxone drug and a new opioid-NSAID combination.
Strategies for a safer, healthier workforce amid COVID-19 and beyond.
All COVID-19 vaccines now have emergency use authorization for a booster dose.
One-third of employees have witnessed cannabis use during work hours.
Pre-pandemic, 951 claims received telemedicine, jumping to 21,000 during the pandemic.
Visit Healthe at WCI booth #913! Plus, a recap of a SAWCA roundtable, featuring Sandy Shtab.
A new migraine medication, various generics, and more.
Long-term health impacts of COVID-19 can complicate claims
A WCRI study found that in some states 17% of workers receive topical analgesics.
Take our survey and share your thoughts on where the industry is headed.
Take part in our virtual speaking sessions at PRIMA and Comp Laude!
The Pfizer vaccine receives full FDA approval, while a new EUA authorizes booster shots for certain populations.
Healthe’s Director of Enterprise Analytics discusses in WorkCompWire how natural language processing can assist with claim review, population management, and more.
Less than 1% of gabapentin prescriptions were prescribed for an FDA-approved diagnosis.
All federal employees are impacted, as are companies with 100 or more employees.
Join our educational session on infectious disease safety in the workplace, and don’t miss a chance to take part in our industry survey!
The FDA approved first-time generics for Xeljanz, two COPD medications, and more.
Healthe’s Director of Product Management explains how centralized data helps claims professionals.
A new WCRI report explores the impact recent opioid legislation has had on injured worker care.
Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.
Not enough time for white papers or industry reports? Check out our Clinical Minute videos!
A joint statement announces that at this time, vaccinated adults are protected from the Delta variant.
Extensive isolation and unique stressors may impact the mental health of remote workers.
Changes center around improving the assessment of mental and behavioral impairment.
Connecticut legalizes recreational use, and NCCI expects even more states to follow suit.
Join our VP of Clinical Services on July 29th for a discussion on care and program considerations for underrepresented populations.
Wegovy (semaglutide) and sotrovimab will soon be available.
How to leverage the patient’s influence over care outcomes.
A new flash report from the WCRI highlights trends in drug utilization.
Corrections officers in Nebraska benefit from a new law; will healthcare workers in Connecticut join them?
Check out Healthe’s latest featured article with WorkCompWire
Join our VP of Clinical Services on July 15th for a discussion on underrepresented populations in workers' comp.
A new 8 mg naloxone nasal spray will soon be available, which is the largest naloxone dose approved by the FDA to date.
The latest issue of Healthesystems’ biannual clinical journal covers trending and influential topics in workers’ comp.
Our VP of Clinical Services comments on opioid alternatives, and our AVP of Advocacy & Compliance discusses social media in the workplace.
Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.
While many states are making decisions regarding gig workers, federal action could soon change things.
After reviewing six rare cases of blood clots after 7 million doses, current data indicates the vaccine is safe.
Applications, benefits and tips for success.
